PF-06263276

• Description :

  PF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC50s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. PF-06263276 inhibits pSTAT3 and TYK2 pathway. PF-06263276 has a protective effect against ear skin inflammation[1].

• UNSPSC :

  12352005

• Target :

  JAK; STAT

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/pf-06263276.html

• Purity :

  99.0

• Solubility :

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles :

  FC1=C(O)C=C(CC)C(C2=CC(NN=C3C4=NC5=C(CN(C(C6=NC=C(N7CCCCC7)N=C6)=O)CC5)N4)=C3C=C2)=C1

• Molecular Formula :

  C31H31FN8O2

• Molecular Weight :

  566.63

• References & Citations :

  [1]Jones P, et al. Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. J Med Chem. 2017 Jan 26;60 (2) :767-786.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  JAK1; JAK2; JAK3; Tyk2

• CAS Number :

  [1421502-62-6]